The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data

Type 2 diabetes (T2D) is associated with numerous comorbidities that significantly reduce quality of life, increase mortality and complicate treatment decisions. In a recent cardiovascular outcomes trial, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Endocrinol
Hlavní autor: Gallwitz, Baptist
Médium: Artigo
Jazyk:Inglês
Vydáno: Touch Medical Media 2018
Témata:
Diabetes
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5954590/
https://ncbi.nlm.nih.gov/pubmed/29922347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2018.14.1.17
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky